抗HMGCR肌病:新西兰全国队列中临床表现的多样性
该研究纳入新西兰75例经线印迹法或酶免疫分析法初筛、免疫沉淀法确认血清抗HMGCR自身抗体阳性的成人患者,描述其临床表现、诊断障碍与结局。72例(96%)以无力为首发症状,22/65(33.8%)以双下肢近端无力为主或唯一表现,18/75(24%)有跌倒;5年生存率92.7%(95%CI 80.6-97.4%),10年生存率82.5%(95%CI 61.2-92.8%)。
要点
- 72/75(96%)以无力起病,22/65(33.8%)以下肢近端无力为主或唯一表现。
- 18/75(24%)出现跌倒,2/75(2.7%)表现为「全身衰退」。
- 4例患者未用免疫抑制即恢复,部分患者仅停用他汀后恢复。
核心结论
- 反复跌倒、长前驱期和以下肢近端为主的无力在该抗HMGCR肌病队列中常见,这些特征与衰弱综合征和散发性包涵体肌炎重叠,强调在该临床背景下应考虑抗HMGCR肌病。
- 少数患者仅停用他汀后即可恢复。
研究设计与样本
- 研究纳入经线印迹法或酶免疫分析法检测血清抗HMGCR自身抗体阳性、随后经免疫沉淀法确认的成人患者,为新西兰全国队列。
主要发现
- 75例患者中,72例(96%)病历记载以无力为首发症状;65例对近端无力有可靠描述,其中22/65(33.8%)描述为以下肢无力为主或仅为下肢无力。
- 45/75(60%)为亚急性起病(症状持续>4周至≤6个月),22/75(29.3%)为更隐匿的慢性起病(症状持续>6个月)。
- 18/75(24%)出现跌倒,2/75(2.7%)表现为「全身衰退」;3例无无力描述,其中2例以肌痛起病、1例以Jessner淋巴细胞性皮疹起病。
- 起病时肌酸激酶中位数为7337 U/L(范围1050-25,500);38例(50.7%)行肌肉活检;合并恶性肿瘤少见。
- 4例患者未用免疫抑制即恢复;5年生存率92.7%(95%CI 80.6-97.4%),10年生存率82.5%(95%CI 61.2-92.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We describe the varied clinical presentations, barriers in diagnosis and outcomes of anti-HMGCR myopathy in a large national cohort. METHODS: Adults found positive for serum anti-HMGCR autoantibodies via line blot or enzyme-immunoassay followed by immunoprecipitation were included in the study. RESULTS: Of 75 patients identified, the records of 72 (96 %) described weakness as the presenting symptom. The records of 65 gave a reliable description of proximal weakness. In 22/65 (33.8 %) the weakness was described as predominantly or solely lower limb weakness. Forty-five of 75 (60 %) presented with a subacute onset (duration of symptoms >4 weeks -≤6 months), whilst 22/75 (29.3 %) presented with a more indolent chronic onset (duration of symptoms >6 months). Eighteen of 75 (24 %) suffered falls and 2/75 (2.7 %) had "general decline". In three patients no weakness was described: two presented with myalgia and one with a skin rash characterized as Jessner lymphocytic skin rash. Median creatine kinase at presentation was 7337 U/L (range 1050-25,500). Muscle biopsy was performed in 38 (50.7 %). Associated malignancy was infrequent. Four patients recovered without immunosuppression. Five-year and 10-year survival was 92.7 % (95 % CI 80.6-97.4 %), and 82.5 % (95 % CI 61.2-92.8 %) respectively. CONCLUSION: Recurrent falls, a long prodrome and dominant lower limb proximal weakness were common in this anti-HMGCR myopathy cohort. These features overlap with frailty syndrome and sporadic inclusion body myositis emphasizing the importance of considering anti-HMGCR myopathy in that clinical context. A minority of patients recover after statin withdrawal alone.
引用
- Chow KL, Keating PE, Solanki K, et al. Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand. Semin Arthritis Rheum. 2024. PMID: 39079206. doi:10.1016/j.semarthrit.2024.152522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。